Miconazole exerts disease-modifying effects during epilepsy by suppressing neuroinflammation via NF-κB pathway and iNOS production

• Published in: Neurobiology of disease Vol. 172; p. 105823
• Main Authors: Gong, Lifen, Zhu, Tao, Chen, Chen, Xia, Ningxiao, Yao, Yinping, Ding, Junchao, Xu, Peng, Li, Shufen, Sun, Zengxian, Dong, Xinyan, Shen, Weida, Sun, Peng, Zeng, Linghui, Xie, Yicheng, Jiang, Peifang
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.2022; Elsevier
• Subjects: iNOS; Miconazole; Neuroinflammation; Neuronal death; NF-κB; Temporal lobe epilepsy; MCZ; CNS; TLE; NF-κB; TRPM2; CA1; KA; PTZ; iNOS; Neuronal death; TGF-β; PILO; qPCR; ASM; Miconazole; AD; MS; EEG; EAE; Neuroinflammation; IL-1β; IL-6; TNF-α; NEUN; GABA; Temporal lobe epilepsy; HPD; ELISA
• ISSN: 0969-9961; 1095-953X
• DOI: 10.1016/j.nbd.2022.105823

Neuroinflammation contributes to the generation of epilepsy and has been proposed as an effective therapeutic target. Recent studies have uncovered the potential effects of the anti-fungal drug miconazole for treating various brain diseases by suppressing neuroinflammation but have not yet been studied in epilepsy. Here, we investigated the effects of different doses of miconazole (5, 20, 80 mg/kg) on seizure threshold, inflammatory cytokines release, and glial cells activation in the pilocarpine (PILO) pentylenetetrazole (PTZ), and intrahippocampal kainic acid (IHKA) models. We demonstrated that 5 and 20 mg/kg miconazole increased seizure threshold, but only 20 mg/kg miconazole reduced inflammatory cytokines release, glial cells activation, and morphological alteration during the early post-induction period (24 h, 3 days). We further investigated the effects of 20 mg/kg miconazole on epilepsy (4 weeks after KA injection). We found that miconazole significantly attenuated cytokines production, glial cells activation, microglial morphological changes, frequency and duration of recurrent hippocampal paroxysmal discharges (HPDs), and neuronal and synaptic damage in the hippocampus during epilepsy. In addition, miconazole suppressed the KA-induced activation of the NF-κB pathway and iNOS production. Our results indicated miconazole to be an effective drug for disease-modifying effects during epilepsy, which may act by attenuating neuroinflammation through the suppression of NF-κB activation and iNOS production. At appropriate doses, miconazole may be a safe and effective approved drug that can easily be repositioned for clinical practice. [Display omitted] •Miconazole collectively elevated seizure threshold.•Miconazole suppressed neuroinflammation and attenuated the development of recurrent hippocampal paroxysm discharges.•Miconazole inhibited neuroinflammation through suppression of the NF-κB pathway and iNOS production.•Miconazole alleviated neuronal death and synaptic loss.